Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre, prospective, of cohort of patients who will receive different doses of allo-depleted lymphocytes .

This project joins in this pioneering worldwide initiative with its own technology based on the use of proteasome inhibitors in vitro, which advantages are, over other methods described, the continuing viability of regulatory T cells and the use of a product to generate allo-depletion that, contrary to those reported by other research groups, it does not pose problems from the point of view of its use or toxicity as we employ a drug widely used clinically by intravenous administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

NCT05126849

Refractory Idiopathic Aplastic Anemia Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

RECRUITING PHASE2

Allogeneic Transplantation From Related Haploidentical Donors

NCT00185692

Blood Cancer Leukemia Graft Versus Host Disease +5 more

COMPLETED PHASE2

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

NCT01087294

Leukemia, B-cell Lymphoma, Hodgkins Lymphoma, Non-hodgkins +1 more

COMPLETED PHASE1

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

NCT00038779

Leukemia Non Hodgkin's Lymphoma Aplastic Anemia

TERMINATED NA

Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies

NCT01566656

Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of the study is to determine the safety of transplantation of hematopoietic progenitors from haploidentical donor with in vitro allo-depleted lymphocyte infusion.

Secondary objectives:

* To assess the immune reconstitution pre and post-infusion of allo-depleted lymphocytes.
* To analyze the incidence of infections (CMV and aspergillus) post-transplant.
* To analyze the impact of acute and chronic graft-versus-host disease (GVHD).
* To optimize the dose of allo-depleted lymphocytes to reconstitute an immune response against pathogens without causing GVHD.
* To assess the rate of graft and myeloid and platelet engraftment time.
* To assess the rate of relapses, event-free survival and overall survival. It is hoped to recruit 20 clinically evaluable patients for safety purpose.

The inclusion period is not more than 2 ½ years. Study duration shall not exceed three years from the inclusion of the first patient. The minimum follow-up of patients is 6 months after transplantation.

The first 5 patients (group 0) will receive haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes and then in cohorts of 3 patients, infuse +4 post-transplant day at doses of: 1x105 cluster of differentiation 3 (CD3)/kg(group 1), 3x105 CD3/kg (group 2), 5x105 CD3 / kg (group 3), 1x106 CD3/kg (group 4) and 3x106 CD3/kg (group 5).

Donor: it is performed one leukapheresis at least 30 days (4 weeks) prior to the scheduled progenitors infusion (day 0), in order to obtain effector T cells.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transplant-Related Hematologic Malignancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

* General condition\> Eastern Cooperative Oncology Group (ECOG) scale 2.
* Left Ventricular ejection fraction (LVEF) \<39%.
* Diffusion capacity of lung for carbon monoxide (DLCO) and forced vital capacity (FVC) \<39% of the theoretical values.
* Impaired liver function (total bilirubin higher than 2 mg / dL and / or transaminases higher than 3 times the normal maximum.
* Creatinine clearance \<50 mL / minute.
* Presence of symptomatic heart, liver cirrhosis or chronic active hepatitis.
* Active tuberculosis.
* Serious diseases which prevent chemotherapy treatments.
* Associated neoplasias (active neoplasias which, according to the opinion of the investigator and the sponsor, could jeopardize patient safety).
* Presence of associated psychiatric pathology.
* HIV infection.

Minimum Eligible Age

16 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No